摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[(1-azabicyclo[2.2.2]oct-3-yl)aminocarbonyl]-2-methylbenzothiophene | 143203-66-1

中文名称
——
中文别名
——
英文名称
3-[(1-azabicyclo[2.2.2]oct-3-yl)aminocarbonyl]-2-methylbenzothiophene
英文别名
N-(1-azabicyclo[2.2.2]octan-3-yl)-2-methyl-1-benzothiophene-3-carboxamide
3-[(1-azabicyclo[2.2.2]oct-3-yl)aminocarbonyl]-2-methylbenzothiophene化学式
CAS
143203-66-1
化学式
C17H20N2OS
mdl
——
分子量
300.425
InChiKey
VEDHJTVDBIOHFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    60.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-[(1-azabicyclo[2.2.2]oct-3-yl)aminocarbonyl]-2-methylbenzothiophene盐酸正丁基锂 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 1.0h, 生成 2-(1-azabicyclo<2.2.2>oct-3-yl)-1,2-dihydrobenzothieno<3,2-c>pyridin-1-one
    参考文献:
    名称:
    2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
    摘要:
    Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
    DOI:
    10.1021/jm00070a008
  • 作为产物:
    参考文献:
    名称:
    2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
    摘要:
    Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
    DOI:
    10.1021/jm00070a008
点击查看最新优质反应信息

文献信息

  • New tricyclic compounds
    申请人:SYNTEX (U.S.A.) INC.
    公开号:EP0485962A2
    公开(公告)日:1992-05-20
    5-HT receptor antagonist compounds of Formula I in which: the dashed line denotes an optional bond; X and Y are independently selected from hydrogen, halogen, hydroxy, lower alkoxy, benzyloxy, lower alkyl, nitro, amino, aminocarbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino; Z is -O-, -S- or -N(R2)-; R1 and R2 are independently selected from hydrogen and lower alkyl or are together -(CH2)n- wherein n is an integer from 2 to 4; and R3 is selected from in which: p is 0 or 1; q is 1, 2 or 3; and R4 is C1 -7 alkyl; their pharmaceutically acceptable salts, individual isomers or mixtures of isomers, processes for their preparation, compositions containing them, and their use.
    式 I 的 5-HT 受体拮抗剂化合物 其中 虚线表示任选键; X 和 Y 独立选自氢、卤素、羟基、低级烷氧基、苄氧基、低级烷基、硝基、氨基、氨基羰基、(低级烷基)氨基、二(低级烷基)氨基和(低级烷酰基)氨基; Z 是-O-、-S-或-N(R2)-; R1 和 R2 分别独立地选自氢和低级烷基,或共同为-(CH2)n-,其中 n 为 2 至 4 的整数;以及 R3 选自 其中 p 是 0 或 1 q是1、2或3;和 R4 是 C1 -7 烷基; 它们的药学上可接受的盐、单个异构体或异构体混合物、它们的制备工艺、含有它们的组合物以及它们的用途。
  • US5189041A
    申请人:——
    公开号:US5189041A
    公开(公告)日:1993-02-23
  • 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
    作者:Robin D. Clark、Aaron B. Miller、Jacob Berger、David B. Repke、Klaus K. Weinhardt、Bruce A. Kowalczyk、Richard M. Eglen、Douglas W. Bonhaus、Chi Ho Lee
    DOI:10.1021/jm00070a008
    日期:1993.9
    Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
查看更多

同类化合物